New anti-tuberculosis drugs in clinical trials with novel mechanisms of action
Tuberculosis is a major health problem worldwide, with approximately 1.7 million people dying annually from the disease. The long current drug regimen, the emergence of drug resistant strains and HIV co-infection have resulted in a resurgence in research efforts to address the urgent need for new an...
| Main Authors: | , |
|---|---|
| Format: | Journal Article |
| Published: |
Elsevier Science Ltd
2008
|
| Online Access: | http://hdl.handle.net/20.500.11937/41035 |
| _version_ | 1848756033380417536 |
|---|---|
| author | Rivers, E. Mancera, Ricardo |
| author_facet | Rivers, E. Mancera, Ricardo |
| author_sort | Rivers, E. |
| building | Curtin Institutional Repository |
| collection | Online Access |
| description | Tuberculosis is a major health problem worldwide, with approximately 1.7 million people dying annually from the disease. The long current drug regimen, the emergence of drug resistant strains and HIV co-infection have resulted in a resurgence in research efforts to address the urgent need for new anti-tuberculosis drugs. A number of new potential anti-tuberculosis drug candidates with novel modes of action have entered clinical trials in recent years. These agents are most likely to be effective against resistant strains. We provide a concise review of their structure-activity relationships, in vitro and in vivo activity, pharmacokinetics, mechanism of action and combination regimens. |
| first_indexed | 2025-11-14T09:05:46Z |
| format | Journal Article |
| id | curtin-20.500.11937-41035 |
| institution | Curtin University Malaysia |
| institution_category | Local University |
| last_indexed | 2025-11-14T09:05:46Z |
| publishDate | 2008 |
| publisher | Elsevier Science Ltd |
| recordtype | eprints |
| repository_type | Digital Repository |
| spelling | curtin-20.500.11937-410352017-09-13T15:58:42Z New anti-tuberculosis drugs in clinical trials with novel mechanisms of action Rivers, E. Mancera, Ricardo Tuberculosis is a major health problem worldwide, with approximately 1.7 million people dying annually from the disease. The long current drug regimen, the emergence of drug resistant strains and HIV co-infection have resulted in a resurgence in research efforts to address the urgent need for new anti-tuberculosis drugs. A number of new potential anti-tuberculosis drug candidates with novel modes of action have entered clinical trials in recent years. These agents are most likely to be effective against resistant strains. We provide a concise review of their structure-activity relationships, in vitro and in vivo activity, pharmacokinetics, mechanism of action and combination regimens. 2008 Journal Article http://hdl.handle.net/20.500.11937/41035 10.1016/j.drudis.2008.09.004 Elsevier Science Ltd restricted |
| spellingShingle | Rivers, E. Mancera, Ricardo New anti-tuberculosis drugs in clinical trials with novel mechanisms of action |
| title | New anti-tuberculosis drugs in clinical trials with novel mechanisms of action |
| title_full | New anti-tuberculosis drugs in clinical trials with novel mechanisms of action |
| title_fullStr | New anti-tuberculosis drugs in clinical trials with novel mechanisms of action |
| title_full_unstemmed | New anti-tuberculosis drugs in clinical trials with novel mechanisms of action |
| title_short | New anti-tuberculosis drugs in clinical trials with novel mechanisms of action |
| title_sort | new anti-tuberculosis drugs in clinical trials with novel mechanisms of action |
| url | http://hdl.handle.net/20.500.11937/41035 |